

Clinical Pre-meeting course Integration of radiotherapy into targeted or immunotherapy ESTRO 2022, 6-10 May 2022, Copenhagen, Denmark

Friday, 6 May 2022, from 08:30 to 17:00

Course directors:

- Professor of Targeted Therapy and Oncologist, CRUK senior group leader and NIHR Senior Clinical Investigator, University of Manchester, Christie Hospital NHS Foundation Trust (UK)
- Eric Deutsch, Radiation Oncologist, Head of the Radiation Oncology Department, Institut de cancérologie Gustave Roussy (FR)

Faculty:

- Amir Abdollahi, Radiation Oncologist, National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center (DE)
- Dirk De Ruyscher, Radiation Oncologist, Maastricht University Medical Center+, Department of Radiation Oncology (Maastro), GROW Oncology (NL)
- Udo Gaipl, Head of Translational Radiobiology Focus Radiation Immunobiology Department of Radiation Oncology, Universitätsklinikum Erlangen (UKER) (DE)
- Jamie Honeychurch, Senior Lecturer, Cancer Immunology and Immunotherapy, University of Manchester (UK)
- Fernanda Herrera, MD, PhD, EORTC chairman, GCG group, Médecin Associé (Senior Physician), Radiation Oncology and Immuno-Oncology Service, Group leader, Lab. Radiation and Onco-Immunology, AGORA ISREC"
- Antonin Levy, Radiation Oncologist, INSERM U1030 Lab Molecular Radiotherapy (FR)
- Lydia Meziani Radiobiology and Immuno-Oncology, Gustave Roussy Cancer Campus (FR)
- Claire Vanpouille-Box, Assistant Professor, Weill Cornell Medicine, (US)
- Anna Wilkins, Clinician Scientist, Institute of Cancer Research and Honorary Consultant, Clinical Oncologist Royal Marsden Hospital (UK)

Time slot	Title	Teacher
8:30 - 9:00	Introduction and welcome	T. Illidge (UK) & E. Deutsch (FR)
9:00 - 9:30	Overview of the innate immune system	L. Meziani (FR)
9:30 - 10:00	Overview of adaptive immune system with a focus on T cells	J. Honeychurch (UK)

Programme

10:00 - 10:30	The cancer immunity cycle and the 5Rs	C. Vanpouille-Box (US)
10:30 - 11:00	COFFEE BREAK	
11:00 - 11:30	The influence of dose, fractionation and volume on the immune response to radiotherapy	F. Herrera (CH)
11:30 - 12:00	Characterising the immune landscape of cancer	A. Wilkins (UK)
12:00 - 12:30	Manipulating the tumour microenvironment to improve radiotherapy response	T. Illidge (UK)
12:30 - 14:00	LUNCH	
14:00 - 14:30	Biomarkers of the immune response to radio(immuno) therapies	U. Gaipl (DE)
14:30 - 15:00	The microbiome and cancer therapy	A. Levy (FR)
15:00 - 15:30	Immunological aspects of the normal tissue response to radiotherapy	A. Abdollahi (DE)
15:30 - 16:00	COFFEE BREAK	
16:00 - 16:30	Radiotherapy and immunotherapy combinations: lessons learnt from clinical trials	E. Deutsch (FR)
16:30 - 17:00	The clinical landscape, progress and challenges in radioimmunotherapy for lung cancer	D. De Ruyscher (NL)
17:00	Close of pre-meeting	